NorthWest Biotherapeutics Inc (NWBO)

[Evaluate]

Manufacturing of DCVax-L ... Jun 5, 2022 presented by Dr. Marnix L. Bosch, MBA, PhD, Chief Technical Officer of NW Bio
at ASCO on June 4, 2022
706 views
Around 12'15: 1 patient = approx 10 - 20 treatments. High yield: 3 - 5 years of doses.
Only 2 grams of tumor tissue needed.
17'30 - 18'40: new automated filling system.
20'50: Shashi & his team made refinements and improvements to the assay, which adds to the functionality of the assay ... NWBO is very happy with this. {Note: I am impressed that he would not only be looking to make improvements to "his" Flaskworks devices, but also helping to improve the manufacturing process of the living cells.}
22'55: turn 2 T-cells into 2,000 T-cells. Rounds of re-stimulation (14 days each). Proof of concept. T-cells capable of killing tumor cells.
High purity, so can inject into the skin rather than into bloodstream.
33'30: DCVax-L can be used for any solid cancer. It has already been used on a compassionate use basis for quite a few patients with a variety of tumors, and a number of the patients were present at the ASCO 2022 event hall.

It would be nice if someone can create a "transcript" of this video.